← Human Trials & Peer-Reviewed Studies
Effect of Vitamin E Supplement on Bone Turnover Markers in Postmenopausal Osteopenic Women: A Double-Blind, Randomized, Placebo-Controlled Trial.
Plain-language guide to PMID 34959779 (2021): double-blind randomized controlled trial of Copper (Supplement) in 52 women, osteoporosis and bone density.
Key Facts
- PMID
- 34959779
- Journal
- Nutrients
- Year
- 2021
- Study type
- Randomized Controlled Trial
- Authors
- Vallibhakara SA et al. (5 authors)
- DOI
- 10.3390/nu13124226
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement) in the context of osteoporosis and bone density, published as a randomized controlled trial.
Vitamin E is a strong anti-oxidative stress agent that affects the bone remodeling process.
This study evaluates the effect of mixed-tocopherol supplements on bone remodeling in postmenopausal osteopenic women.
Who Took Part
According to the abstract, 52 women were involved.
The age groups tagged for this paper are middle-aged adults and older adults, women only.
All 52 osteopenic postmenopausal women were enrolled and allocated into two groups.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.
Neither the women nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
What Was Measured
This study evaluates the effect of mixed-tocopherol supplements on bone remodeling in postmenopausal osteopenic women.
Topics PubMed links to this paper include Biomarkers, Bone Diseases, Metabolic, Bone Remodeling, Bone Resorption, Collagen Type I, Dietary Supplements and Intention to Treat Analysis.
The authors tagged it with the keywords bone health, bone marker turnover, bone turnover, osteopenia, postmenopausal women and tocopherol.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 52 women in people with osteoporosis and bone density.
The publication is from 2021 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, Osteoporosis and bone density research.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.